EphA2 Minibody PET Imaging Lights Up Cancer Tumors
A new EphA2 minibody PET imaging method from the University of Missouri lights up cancer tumors during a PET scan. The work could help clinicians quickly find patients best suited to receive targeted cancer therapies.
The team built a very small antibody that hunts down EphA2, a protein often found on cancer cells. After making the antibody, they added a radioactive tag that lets the molecule show up on a positron emission tomography (PET) scan.
How the EphA2 minibody PET imaging works
Barry Edwards, associate professor of biochemistry in the School of Medicine, designed the small antibody. Edwards also has an appointment in the College of Arts and Science.
The minibody seeks EphA2 on tumor cell surfaces. The radioactive tag on the minibody emits a signal that a PET scanner picks up. In a scan, the tumor glows where EphA2 is abundant. Healthy tissue stays dark.
That contrast is the core idea of the new EphA2 minibody PET imaging method. It lets clinicians see at a glance which tumors carry high amounts of the target protein.
What the mouse experiments showed
In experiments in mice, the cancer detecting "flashlight" clearly lit up tumors expressing EphA2. The signal tracked the protein, not just the tumor mass.
The findings hint that the labeled antibody could help clinicians spot cancers carrying this protein. It could also help flag which patients might respond to drugs aimed at EphA2-bearing tumor cells.
That selectivity matters. Many cancer drugs hit both tumor and normal cells. Knowing the EphA2 status up front helps clinicians choose drugs that strike tumor cells while sparing normal tissue.
Why patient selection matters
"By finding out which patients have high or low amounts of EphA2, we can determine who is most likely to benefit from a targeted cancer treatment," said Edwards. He added the new process saves time and money while advancing precision medicine.
Patient selection is now key in cancer care. Companion tests that pair with targeted drugs are now standard for several cancers. A PET readout of EphA2 status could act as a noninvasive test for any future EphA2 drug.
Faster and less invasive than current methods
Doctors today lean on biopsies and MRI scans to assess tumors. These methods can be invasive. They take time. They give limited insight into which proteins sit inside cancer cells.
Edwards works with imaging tools at Mizzou's Molecular Imaging and Theranostics Center. He hopes to move the EphA2 minibody PET imaging from preclinical work into first-in-human trials within about seven years.
"This new targeted approach is noninvasive, and you can get results from the imaging in hours rather than days, which can be huge for patients traveling long distances to seek treatment," Edwards said. "By making the process easier and faster for both patients and clinicians, we're showing that precision medicine is a win-win."
Hours-not-days turnaround shifts the patient workflow. Rural patients who travel for cancer care, or those who wait days for biopsy results, could get answers in one visit.
What the study covered
The study, titled "Preclinical evaluation of anti-EphA2 minibody-based immunoPET agent as a diagnostic tool for cancer," was published in Molecular Imaging and Biology. The team focused on the minibody design and the PET signal in mouse models of EphA2 tumors.
They showed clear tumor uptake of the radiolabeled minibody. They also showed strong contrast against background tissue. Those are the two main checks before any imaging agent can move to human trials.
What comes next
The next steps are larger preclinical safety and dosimetry studies. After that, the team will design first-in-human imaging trials. The seven-year target Edwards cited fits the usual path for new radiopharmaceuticals.
The EphA2 minibody PET imaging work also opens a theranostic path. Pairing the diagnostic minibody with a treatment radioisotope on the same scaffold would let doctors see and treat EphA2 tumors. Many academic and industry teams already work on this path.
EphA2 minibody PET imaging is still preclinical. But the workflow gains are clear for PET centers, oncology programs, and theranostic units. Coverage on Medigear.uk shows why oncology teams must track how EphA2 minibody PET imaging findings shape precision cancer care.
Source: Originating coverage based on University of Missouri press materials on the Edwards et al. paper in Molecular Imaging and Biology. Barry Edwards, associate professor of biochemistry, University of Missouri School of Medicine, and College of Arts and Science. Imaging work performed at Mizzou's Molecular Imaging and Theranostics Center. Study title: "Preclinical evaluation of anti-EphA2 minibody-based immunoPET agent as a diagnostic tool for cancer."
